CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 108 enrolled
Drug / intervention
Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinomaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02664792
NCT02664792N/ACompleted
CompareCT.gov

Use of [18]F-FDG - PET/CT in Brazil Unified Health System (SUS) as an Alternative Non-invasive Method for Staging of Lung Cancer

Latin American Cooperative Oncology Group·interventional·Posted Jan 27, 2016·Updated Feb 23, 2017

In Brief

A clinical study evaluating Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma for Non-small Cell Lung Carcinoma. Completed, enrolled 108 participants across 1 site.

Detailed Summary

To evaluate the diagnostic accuracy of the 18Fluor-fluorodeoxyglucose (\[18F\]FDG) in the Positron Emission Tomography/Computed Tomography (PET/CT) as compared to mediastinoscopy for staging of non-small cel lung carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Carcinoma
CountriesBrazil
CollaboratorsInstituto do Cérebro do Rio Grande do Sul - InsCer, Conselho Nacional de Desenvolvimento Científico e Tecnológico

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 27, 2016
Enrollment StartAug 1, 2014
Primary CompletionJul 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.4 years ago

Interventions

Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinomaother